<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00910117</url>
  </required_header>
  <id_info>
    <org_study_id>HNTG 09-01</org_study_id>
    <nct_id>NCT00910117</nct_id>
  </id_info>
  <brief_title>Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)</brief_title>
  <official_title>Phase II Study of Nimotuzumab Plus PF as Induction Chemotherapy in Patients With Locally Advanced HNSCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the role of nimotuzumab in the neo-adjuvant setting in
      patients with locally advanced HNSCC. The hypothesis is that the response would be increased
      with the combination of nimotuzumab and cisplatin and fluorouracil (PF) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction chemotherapy followed by radiotherapy is the standard treatment for patients with
      unresectable HNSCC. However, the role of induction chemotherapy remains uncertain for
      resectable disease. Therefore, we plan to perform a phase II study to evaluate it, focusing
      on radiographic and pathologic response after induction chemotherapy. Moreover, a new EGFR
      monoclonal antibody (nimotuzumab) is incorporated with PF regimen. The hypothesis is the
      addition of nimotuzumab would improve the response without remarkably increase the toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>pathologic complete response</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>nimotuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nimotuzumab plus PF regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nimotuzumab</intervention_name>
    <description>nimotuzumab 400 mg d1</description>
    <arm_group_label>nimotuzumab</arm_group_label>
    <other_name>h-R3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF regimen (cisplatin and 5-FU)</intervention_name>
    <description>cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5</description>
    <arm_group_label>nimotuzumab</arm_group_label>
    <other_name>PF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age range 18-70 years old

          -  ECOG performance status 0-1

          -  Histologically confirmed and potentially resectable locally advanced (T2-4, N0-3, M0)
             HNSCC

          -  Adequate organ function

        Exclusion Criteria:

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Pregnant or lactating women

          -  Serious uncontrolled diseases and intercurrent infection

          -  Previous serious cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ye Guo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>February 16, 2012</last_update_submitted>
  <last_update_submitted_qc>February 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Ye Guo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>induction chemotherapy</keyword>
  <keyword>nimotuzumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

